Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: A potential major issue for anti-ALK therapeutic strategies

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 238-244

  Ilie, M I ^a,b   Bence, C ^a   Hofman, V ^a,b,c   Long Mira, E ^a,b   Butori, C ^a   Bouhlel, L ^a   Lalvee S ^a   Mouroux, J ^a,b   Poudenx, M ^a   Otto, J ^d   Marquette, C H ^a,b   Hofman, Paul ^a,b,c  

^a PASTEUR HOSPITAL   (France)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^c Hospital Integrated Biobank   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

ALK; Crizotinib; Discrepancy; Fluorescence in situ hybridization; Immunohistochemistry; Lung adenocarcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; MET PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

ADULT; AGED; ALK GENE; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COPY NUMBER VARIATION; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PROTEIN EXPRESSION; VERY ELDERLY; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GENE DOSAGE; GENETIC VARIABILITY; GENETIC VARIATION; GENETICS; LUNG NEOPLASMS; MORTALITY; PROCEDURES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE DOSAGE; GENE REARRANGEMENT; GENETIC VARIATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84922540993     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu484     Document Type: Article

References (30)

1. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
2. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
3. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
4. Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011; 6: 942-946.
5. Schwab R, Petak I, Kollar M et al. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 2014; 83: 109-111.
6. Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-870.
7. Heigener DF, Reck M. Crizotinib. Recent Results Cancer Res 2014; 201: 197-205.
8. Camidge DR, Theodoro M, Maxson DA et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 2012; 118: 4486-4494.
9. Ilie M, Hofman P. The potential value of immunohistochemistry as a screening tool for oncogenic targets of personalized lung cancer therapy. J Oncopathol 2013; 1: 1.
10. Weickhardt AJ, Aisner DL, Franklin WA et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013; 119: 1467-1477.
11. Conklin CM, Craddock KJ, Have C et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 2013; 8: 45-51.
12. Hofman P, Ilie M, Hofman V et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012; 23: 1738-1743.
13. Minca EC, Portier BP, Wang Z et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 2013; 15: 341-346.
14. Wynes MW, Sholl LM, Dietel M et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 2014; 9: 631-638.
15. Peled N, Palmer G, Hirsch FR et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012; 7: e14-e16.
16. Sun JM, Choi YL, Won JK et al. A dramatic response to crizotinib in a non-smallcell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 2012; 7: e36-e38.
17. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18: 1472-1482.
18. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
19. Gainor JF, Varghese AM, Ou SH et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013; 19: 4273-4281.
20. Martelli MP, Sozzi G, Hernandez L et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009; 174: 661-670.
21. Hutarew G, Hauser-Kronberger C, Strasser F et al. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. Histopathology 2014; 65: 398-407.
22. Camidge DR, Skokan M, Kiatsimkul P et al. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer 2013; 119: 3968-3975.
23. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16: 1561-1571.
24. Takeuchi K, Choi YL, Togashi Y et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143-3149.
25. Feng Y, Minca EC, Lanigan C et al. High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer. J Thorac Oncol 2014; 9: 646-653.
26. Salido M, Pijuan L, Martinez-Aviles L et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011; 6: 21-27.
27. Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 2012; 9: 268-277.
28. Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012; 4: 120ra117.
29. Khadija K, Auger N, Lueza B et al. ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report. J Clin Oncol 2012; 30: Abstract 10556.
30. Cabillic F, Gros A, Dugay F et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 2014; 9: 295-306.